The Janus kinase 1 inhibitor abrocitinib for the treatment of oral lichen planus-Reference-Cited by-同舟云学术

The Janus kinase 1 inhibitor abrocitinib for the treatment of oral lichen planus

Published:2023-04-07 Issue:8 Volume:37 Page:
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:Acad Dermatol Venereol

Author:

Solimani Farzan¹²^ORCID,Mesas‐Fernández Alberto¹,Dilling Amrei¹,Nast Alexander¹^ORCID,Hilke Franz J.¹,Ghoreschi Franziska C.¹,Worm Margitta¹,Ghoreschi Kamran¹^ORCID,Meier Katharina¹^ORCID

Affiliation:

1. Department of Dermatology, Venereology and Allergology Charité‐Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt‐Universität zu Berlin Charitéplatz 1 10117 Berlin Germany

2. Berlin Institute of Health at Charité – Universitätsmedizin Berlin, BIH Biomedical Innovation Academy, BIH Charité Clinician Scientist Program Charitéplatz 1 10117 Berlin Germany

Funder

Deutsche Forschungsgemeinschaft

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdv.19069

Reference10 articles.

1. Lichen planus – a clinical guide;Solimani F;J Dtsch Dermatol Ges,2021

2. The critical role of IFNγ in the epidermotropic migration of lymphocytes in oral lichen planus

3. FoxP3+CD4+, IFN-γ+CD4+, and IFN-γ+CD8+ cell levels in erosive and non-erosive types of oral lichen planus patients